DOI QR코드

DOI QR Code

Clinico-pathological Profile of Lung Cancer at AIIMS: A Changing Paradigm in India

  • Malik, Prabhat Singh (Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Sharma, Mehar Chand (Department of Pathology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Mohanti, Bidhu Kalyan (Department of Radiation Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Shukla, N.K. (Department of Surgical Oncoloy, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Deo, S.V.S. (Department of Surgical Oncoloy, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Mohan, Anant (Department of Pulmonary Medicine, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Kumar, Guresh (Department of Biostatistics, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences) ;
  • Raina, Vinod (Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences)
  • Published : 2013.01.31

Abstract

Background: Lung cancer is one of the commonest and most lethal cancers throughout the world. The epidemiological and pathological profile varies among different ethnicities and geographical regions. At present adenocarcinoma is the commonest histological subtype of non-small cell lung cancer (NSCLC) in most of the Western and Asian countries. However, in India squamous cell carcinoma has been reported as the commonest histological type in most of the series. The aim of the study was to analyze the current clinico-pathological profile and survival of lung cancer at our centre. Materials and Methods: We analyzed 434 pathologically confirmed lung cancer cases registered at our centre over a period of three years. They were evaluated for their clinical and pathological profiles, treatment received and outcome. The available histology slides were reviewed by an independent reviewer. Results: Median age was 55 years with a male:female ratio of 4.6:1. Some 68% of patients were smokers. There were 85.3% NSCLC and 14.7% SCLC cases. Among NSCLCs, adenocarcinoma was the commonest histological subtype after the pathology review. Among NSCLC, 56.8% cases were of stage IV while among SCLC 71.8% cases had extensive stage disease. Some 29% of patients did not receive any anticancer treatment. The median overall and progression free survivals of the patients who received treatment were 12.8 and 7.8 months for NSCLC and 9.1 and 6.8 months for SCLC. Conclusions: This analysis suggests that adenocarcinoma may now be the commonest histological subtype also in India, provided a careful pathological review is done. Most of the patients present at advanced stage and outcome remains poor.

References

  1. Field RW, Smith BJ, Platz CE, et al (2004). Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review. J Natl Cancer Inst, 96, 1105-7. https://doi.org/10.1093/jnci/djh189
  2. Fry WA, Phillips JL, Menck HR.(1999). Ten-year survey of lung cancer treatment and survival in hospitals in the United States: a national cancer data base report. Cancer, 86, 1867-76. https://doi.org/10.1002/(SICI)1097-0142(19991101)86:9<1867::AID-CNCR31>3.0.CO;2-9
  3. Giovino GA (2002). Epidemiology of tobacco use in the United States. Oncogene, 21, 7326-40. https://doi.org/10.1038/sj.onc.1205808
  4. Govindan R, Page N, Morgensztern D, et al (2006). Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol, 24, 4539-44. https://doi.org/10.1200/JCO.2005.04.4859
  5. Grivaux M, Zureik M, Marsal L, et al.(2011). Five-year survival for lung cancer patients managed in general hospitals. Rev Mal Respir, 28, 31-8. https://doi.org/10.1016/j.rmr.2008.07.001
  6. Janssen-Heijnen MLG, Coebergh J-WW (2003). The changing epidemiology of lung cancer in Europe. Lung Cancer, 41, 245-58. https://doi.org/10.1016/S0169-5002(03)00230-7
  7. Khan NA, Afroz F, Lone MM, et al (2006). Profile of lung cancer in Kashmir, India: a five-year study. Indian J Chest Dis Allied Sci, 48, 187-90.
  8. Mahmud SM, Reilly M, Comber H (2003). Patterns of initial management of lung cancer in the Republic of Ireland: a population-based observational study. Lung Cancer, 41, 57-64. https://doi.org/10.1016/S0169-5002(03)00148-X
  9. Mohan A, Goyal A, Singh P, et al (2006). Survival in small cell lung cancer in India: prognostic utility of clinical features, laboratory parameters and response to treatment. Indian J Cancer, 43, 67-74. https://doi.org/10.4103/0019-509X.25887
  10. Parkin DM FJ. GLOBOCAN 2008 V1.2, Cancer Incidence and Mortality Worldwide [Internet]. IARC Cancer Base No.10; Available from: http://globocan.iarc.fr
  11. Prasad R, James P, Kesarwani V, et al (20004). Clinicopathological study of bronchogenic carcinoma. Respirology, 9, 557-60. https://doi.org/10.1111/j.1440-1843.2004.00600.x
  12. Scagliotti G, Brodowicz T, Shepherd FA, et al (2011). Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer. J Thorac Oncol, 6, 64-70
  13. Singh N, Aggarwal AN, Gupta D, et al (2010). Unchanging clinico-epidemiological profile of lung cancer in north India over three decades. Cancer Epidemiol, 34, 101-4. https://doi.org/10.1016/j.canep.2009.12.015
  14. Standfield L, Weston AR, Barraclough H, et al (2011). Histology as a treatment effect modifier in advanced non-small cell lung cancer: a systematic review of the evidence. Respirology, 16, 1210-20. https://doi.org/10.1111/j.1440-1843.2011.02025.x
  15. Stevens W, Stevens G, Kolbe J, et al (2007). Lung cancer in New Zealand: patterns of secondary care and implications for survival. J Thorac Oncol, 2, 481-93. https://doi.org/10.1097/JTO.0b013e31805fea3a
  16. Thun MJ, Henley SJ, Burns D, et al. (2006). Lung cancer death rates in lifelong nonsmokers. J Natl Cancer Inst, 98, 691-9. https://doi.org/10.1093/jnci/djj187
  17. Valaitis J, Warren S, Gamble D (1981). Increasing incidence of adenocarcinoma of the lung. Cancer, 47, 1042-6. https://doi.org/10.1002/1097-0142(19810301)47:5<1042::AID-CNCR2820470535>3.0.CO;2-5
  18. Albain KS, Crowley JJ, LeBlanc M, et al (1990). Determinants of improved outcome in small-cell lung cancer: an analysis of the 2,580-patient southwest oncology group data base. J Clin Oncol, 8, 1563-74.
  19. Albain KS, Crowley JJ, LeBlanc M, et al (1991). Survival determinants in extensive-stage non-small-cell lung cancer: the southwest oncology group experience. J Clin Oncol, 9, 1618-26.
  20. Behera D, Balamugesh T (2004). Lung cancer in India. Indian J Chest Dis Allied Sci, 46, 269-81.
  21. Blanchon F, Grivaux M, Asselain B, et al (2006). 4-year mortality in patients with non-small-cell lung cancer: development and validation of a prognostic index. Lancet Oncol, 7, 829-36. https://doi.org/10.1016/S1470-2045(06)70868-3
  22. Cetin K, Ettinger DS, Hei Y-J, et al (2011). Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clin Epidemiol, 3, 139-48.
  23. Cooper WA, O'toole S, Boyer M, et al (2011). What' new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology, 43, 103-15. https://doi.org/10.1097/PAT.0b013e328342629d
  24. Cykert S, Dilworth-Anderson P, Monroe MH, et al (2010). Factors associated with decisions to undergo surgery among patients with newly diagnosed early-stage lung cancer. JAMA, 303, 2368-76. https://doi.org/10.1001/jama.2010.793
  25. Delaney G, Jacob S, Featherstone C, et al (2005). The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer, 104, 1129-37. https://doi.org/10.1002/cncr.21324
  26. Eisenhauer EA, Therasse P, Bogaerts J, et al (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer, 45, 228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  27. Erridge SC, Murray B, Price A, et al (2008). Improved treatment and survival for lung cancer patients in South-East Scotland. J Thorac Oncol, 3, 491-8. https://doi.org/10.1097/JTO.0b013e31816fca46
  28. Esnaola NF, Gebregziabher M, Knott K, et al (2008). Underuse of surgical resection for localized, non-small cell lung cancer among whites and African Americans in South Carolina. Ann Thorac Surg, 86, 220-6. https://doi.org/10.1016/j.athoracsur.2008.02.072
  29. Ettinger DS. NCCN Clinical Practice Guidelines in Oncology for Non Small Cell Lung Cancer, Ver 2.2012 [Internet]. Natinal Comprehensive Cancer Network; 2012. Available from: www.nccn.com
  30. Vineis P, Alavanja M, Buffler P, et al (2004). Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst, 96, 99-106. https://doi.org/10.1093/jnci/djh014
  31. Vinod SK, O’Connell DL, Simonella L, et al (2008). Gaps in optimal care for lung cancer. J Thorac Oncol, 3, 871-9. https://doi.org/10.1097/JTO.0b013e31818020c3
  32. Vinod SK, Sidhom MA, Gabriel GS, et al (2010). Why do some lung cancer patients receive no anticancer treatment? J Thorac Oncol, 5, 1025-32.
  33. Wakelee HA, Chang ET, Gomez SL, et al (2007). Lung cancer incidence in never smokers. J Clin Oncol, 25, 472-8. https://doi.org/10.1200/JCO.2006.07.2983

Cited by

  1. Prognostic Value of Phosphorylated mTOR/RPS6KB1 in Non-small Cell Lung Cancer vol.14, pp.6, 2013, https://doi.org/10.7314/APJCP.2013.14.6.3725
  2. Clinical Observations on the Association Between Diagnosis of Lung Cancer and Serum Tumor Markers in Combination vol.14, pp.7, 2013, https://doi.org/10.7314/APJCP.2013.14.7.4369
  3. Edition Staging System vol.15, pp.6, 2014, https://doi.org/10.7314/APJCP.2014.15.6.2465
  4. Hematologic Toxicity in Patients Undergoing Radical Anti-cancer Therapy: A Cross-Sectional Analysis of Patients in an Oncology Ward in India vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3587
  5. Clinical Evaluation of Tumor Markers for Diagnosis in Patients with Non-small Cell Lung Cancer in China vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.4891
  6. Association of p53 and mdm2 in the development and progression of non-small cell lung cancer vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3208-6
  7. Role of survivin re-expression in the development and progression of non-small cell lung cancer vol.36, pp.7, 2015, https://doi.org/10.1007/s13277-015-3224-6
  8. Clinico-Pathological Profile and Haematological Abnormalities Associated with Lung Cancer in Bangalore, India vol.16, pp.18, 2016, https://doi.org/10.7314/APJCP.2015.16.18.8235
  9. Efficacy of 18F-fluorodeoxyglucose positron emission tomography/computed tomography as a predictor of response in locally advanced non-small-cell carcinoma of the lung vol.37, pp.2, 2016, https://doi.org/10.1097/MNM.0000000000000422
  10. Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: evaluation of response, survival, toxicity and quality of life from a Phase II randomized study vol.89, pp.1062, 2016, https://doi.org/10.1259/bjr.20150966
  11. Surgery for lung cancer—the Indian scenario vol.34, pp.S1, 2018, https://doi.org/10.1007/s12055-017-0634-7